The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
2 Comments
Recent Posts
Why Ottawa Will Likely Join the U.S. in Opposing the Quebec Online Streaming Law at the Centre of the Trade Battle 
Online Harms’ Forgotten Generation: Why the Government Needs to Pay Attention to Protecting Seniors 
Culture Off the Table? What the Collapsed Canada-U.S. Trade Talks Reveal About the Carney Government’s Cultural Policy 
Digital Trade Alignment: What May Be in Play in the Canada-U.S. Trade Deal 
TMU Picks Damage Control Over Fixing the Damage: Behind Its Shameful Response to the Devastating Benotto Report on Campus Antisemitism
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.